blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2796462

EP2796462 - ANTI-TUMOR PEPTIDE AND USE THEREFOR [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  25.05.2018
Database last updated on 22.08.2024
FormerThe patent has been granted
Status updated on  16.06.2017
FormerGrant of patent is intended
Status updated on  09.06.2017
FormerExamination is in progress
Status updated on  16.05.2017
FormerGrant of patent is intended
Status updated on  02.01.2017
Most recent event   Tooltip17.07.2020Lapse of the patent in a contracting state
New state(s): AL		published on 19.08.2020  [2020/34]
Applicant(s)For all designated states
Toagosei Co., Ltd.
1-14-1, Nishi Shimbashi
Minato-ku
Tokyo 105-8419 / JP
[2017/20]
Former [2014/44]For all designated states
Toagosei Co., Ltd
1-14-1, Nishi shimbashi
Minato-ku, Tokyo 105-8419 / JP
Inventor(s)01 / KOBAYASHI, Nahoko
C/O TOAGOSEI CO., LTD.
2, Ookubo
Tsukuba-shi Ibaraki 300-2611 / JP
02 / YOSHIDA, Tetsuhiko
C/O TOAGOSEI CO., LTD.
2, Ookubo
Tsukuba-shi Ibaraki 300-2611 / JP
 [2017/20]
Former [2014/44]01 / KOBAYASHI, Nahoko
C/O TOAGOSEI CO. LTD.
2 Ookubo
Tsukuba-shi Ibaraki 300-2611 / JP
02 / YOSHIDA, Tetsuhiko
C/O TOAGOSEI CO. LTD.
2 Ookubo
Tsukuba-shi Ibaraki 300-2611 / JP
Representative(s)Elsy, David
Withers & Rogers LLP
2 London Bridge
London SE1 9RA / GB
[N/P]
Former [2014/44]Elsy, David
Withers & Rogers LLP
4 More London Riverside
London SE1 2AU / GB
Application number, filing date12860097.020.12.2012
[2017/29]
WO2012JP83109
Priority number, dateJP2011027897320.12.2011         Original published format: JP 2011278973
JP2011027897420.12.2011         Original published format: JP 2011278974
[2014/44]
Filing languageJA
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2013094697
Date:27.06.2013
Language:JA
[2013/26]
Type: A1 Application with search report 
No.:EP2796462
Date:29.10.2014
Language:EN
[2014/44]
Type: B1 Patent specification 
No.:EP2796462
Date:19.07.2017
Language:EN
[2017/29]
Search report(s)International search report - published on:JP27.06.2013
(Supplementary) European search report - dispatched on:EP29.05.2015
ClassificationIPC:C07K7/06, A61K38/00, A61P35/00, A61P35/02, C07K19/00
[2014/44]
CPC:
C07K7/08 (EP,US); A61K38/08 (EP,US); A61P35/00 (EP);
A61P35/02 (EP); A61P43/00 (EP); C07K7/06 (EP,US)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2014/44]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:ANTITUMORPEPTID UND VERWENDUNG DAFÜR[2014/44]
English:ANTI-TUMOR PEPTIDE AND USE THEREFOR[2014/44]
French:PEPTIDE ANTITUMORAL ET SON UTILISATION[2014/44]
Entry into regional phase17.06.2014Translation filed 
17.06.2014National basic fee paid 
17.06.2014Search fee paid 
17.06.2014Designation fee(s) paid 
17.06.2014Examination fee paid 
Examination procedure17.06.2014Examination requested  [2014/44]
18.08.2015Amendment by applicant (claims and/or description)
14.03.2016Despatch of a communication from the examining division (Time limit: M02)
18.05.2016Reply to a communication from the examining division
03.01.2017Communication of intention to grant the patent
11.05.2017Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
11.05.2017Fee for grant paid
11.05.2017Fee for publishing/printing paid
08.06.2017Information about intention to grant a patent
08.06.2017Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  14.03.2016
Opposition(s)20.04.2018No opposition filed within time limit [2018/26]
Fees paidRenewal fee
11.12.2014Renewal fee patent year 03
09.12.2015Renewal fee patent year 04
09.12.2016Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU20.12.2012
AL19.07.2017
AT19.07.2017
CY19.07.2017
CZ19.07.2017
DK19.07.2017
EE19.07.2017
ES19.07.2017
FI19.07.2017
HR19.07.2017
IT19.07.2017
LT19.07.2017
LV19.07.2017
MC19.07.2017
MK19.07.2017
NL19.07.2017
PL19.07.2017
PT19.07.2017
RO19.07.2017
RS19.07.2017
SE19.07.2017
SI19.07.2017
SK19.07.2017
SM19.07.2017
TR19.07.2017
BG19.10.2017
NO19.10.2017
GR20.10.2017
IS19.11.2017
IE20.12.2017
LU20.12.2017
MT20.12.2017
BE31.12.2017
CH31.12.2017
LI31.12.2017
[2020/34]
Former [2020/28]HU20.12.2012
AT19.07.2017
CY19.07.2017
CZ19.07.2017
DK19.07.2017
EE19.07.2017
ES19.07.2017
FI19.07.2017
HR19.07.2017
IT19.07.2017
LT19.07.2017
LV19.07.2017
MC19.07.2017
MK19.07.2017
NL19.07.2017
PL19.07.2017
PT19.07.2017
RO19.07.2017
RS19.07.2017
SE19.07.2017
SI19.07.2017
SK19.07.2017
SM19.07.2017
TR19.07.2017
BG19.10.2017
NO19.10.2017
GR20.10.2017
IS19.11.2017
IE20.12.2017
LU20.12.2017
MT20.12.2017
BE31.12.2017
CH31.12.2017
LI31.12.2017
Former [2020/15]HU20.12.2012
AT19.07.2017
CY19.07.2017
CZ19.07.2017
DK19.07.2017
EE19.07.2017
ES19.07.2017
FI19.07.2017
HR19.07.2017
IT19.07.2017
LT19.07.2017
LV19.07.2017
MC19.07.2017
MK19.07.2017
NL19.07.2017
PL19.07.2017
RO19.07.2017
RS19.07.2017
SE19.07.2017
SI19.07.2017
SK19.07.2017
SM19.07.2017
TR19.07.2017
BG19.10.2017
NO19.10.2017
GR20.10.2017
IS19.11.2017
IE20.12.2017
LU20.12.2017
MT20.12.2017
BE31.12.2017
CH31.12.2017
LI31.12.2017
Former [2019/51]HU20.12.2012
AT19.07.2017
CY19.07.2017
CZ19.07.2017
DK19.07.2017
EE19.07.2017
ES19.07.2017
FI19.07.2017
HR19.07.2017
IT19.07.2017
LT19.07.2017
LV19.07.2017
MC19.07.2017
MK19.07.2017
NL19.07.2017
PL19.07.2017
RO19.07.2017
RS19.07.2017
SE19.07.2017
SI19.07.2017
SK19.07.2017
SM19.07.2017
BG19.10.2017
NO19.10.2017
GR20.10.2017
IS19.11.2017
IE20.12.2017
LU20.12.2017
MT20.12.2017
BE31.12.2017
CH31.12.2017
LI31.12.2017
Former [2019/47]HU20.12.2012
AT19.07.2017
CY19.07.2017
CZ19.07.2017
DK19.07.2017
EE19.07.2017
ES19.07.2017
FI19.07.2017
HR19.07.2017
IT19.07.2017
LT19.07.2017
LV19.07.2017
MC19.07.2017
NL19.07.2017
PL19.07.2017
RO19.07.2017
RS19.07.2017
SE19.07.2017
SI19.07.2017
SK19.07.2017
SM19.07.2017
BG19.10.2017
NO19.10.2017
GR20.10.2017
IS19.11.2017
IE20.12.2017
LU20.12.2017
MT20.12.2017
BE31.12.2017
CH31.12.2017
LI31.12.2017
Former [2019/31]HU20.12.2012
AT19.07.2017
CZ19.07.2017
DK19.07.2017
EE19.07.2017
ES19.07.2017
FI19.07.2017
HR19.07.2017
IT19.07.2017
LT19.07.2017
LV19.07.2017
MC19.07.2017
NL19.07.2017
PL19.07.2017
RO19.07.2017
RS19.07.2017
SE19.07.2017
SI19.07.2017
SK19.07.2017
SM19.07.2017
BG19.10.2017
NO19.10.2017
GR20.10.2017
IS19.11.2017
IE20.12.2017
LU20.12.2017
MT20.12.2017
BE31.12.2017
CH31.12.2017
LI31.12.2017
Former [2019/30]AT19.07.2017
CZ19.07.2017
DK19.07.2017
EE19.07.2017
ES19.07.2017
FI19.07.2017
HR19.07.2017
IT19.07.2017
LT19.07.2017
LV19.07.2017
MC19.07.2017
NL19.07.2017
PL19.07.2017
RO19.07.2017
RS19.07.2017
SE19.07.2017
SI19.07.2017
SK19.07.2017
SM19.07.2017
BG19.10.2017
NO19.10.2017
GR20.10.2017
IS19.11.2017
IE20.12.2017
LU20.12.2017
MT20.12.2017
BE31.12.2017
CH31.12.2017
LI31.12.2017
Former [2018/52]AT19.07.2017
CZ19.07.2017
DK19.07.2017
EE19.07.2017
ES19.07.2017
FI19.07.2017
HR19.07.2017
IT19.07.2017
LT19.07.2017
LV19.07.2017
NL19.07.2017
PL19.07.2017
RO19.07.2017
RS19.07.2017
SE19.07.2017
SI19.07.2017
SK19.07.2017
SM19.07.2017
BG19.10.2017
NO19.10.2017
GR20.10.2017
IS19.11.2017
IE20.12.2017
LU20.12.2017
MT20.12.2017
BE31.12.2017
CH31.12.2017
LI31.12.2017
Former [2018/50]AT19.07.2017
CZ19.07.2017
DK19.07.2017
EE19.07.2017
ES19.07.2017
FI19.07.2017
HR19.07.2017
IT19.07.2017
LT19.07.2017
LV19.07.2017
NL19.07.2017
PL19.07.2017
RO19.07.2017
RS19.07.2017
SE19.07.2017
SI19.07.2017
SK19.07.2017
SM19.07.2017
BG19.10.2017
NO19.10.2017
GR20.10.2017
IS19.11.2017
IE20.12.2017
LU20.12.2017
MT20.12.2017
BE31.12.2017
Former [2018/45]AT19.07.2017
CZ19.07.2017
DK19.07.2017
EE19.07.2017
ES19.07.2017
FI19.07.2017
HR19.07.2017
IT19.07.2017
LT19.07.2017
LV19.07.2017
NL19.07.2017
PL19.07.2017
RO19.07.2017
RS19.07.2017
SE19.07.2017
SI19.07.2017
SK19.07.2017
SM19.07.2017
BG19.10.2017
NO19.10.2017
GR20.10.2017
IS19.11.2017
IE20.12.2017
LU20.12.2017
MT20.12.2017
Former [2018/43]AT19.07.2017
CZ19.07.2017
DK19.07.2017
EE19.07.2017
ES19.07.2017
FI19.07.2017
HR19.07.2017
IT19.07.2017
LT19.07.2017
LV19.07.2017
NL19.07.2017
PL19.07.2017
RO19.07.2017
RS19.07.2017
SE19.07.2017
SI19.07.2017
SK19.07.2017
SM19.07.2017
BG19.10.2017
NO19.10.2017
GR20.10.2017
IS19.11.2017
LU20.12.2017
MT20.12.2017
Former [2018/39]AT19.07.2017
CZ19.07.2017
DK19.07.2017
EE19.07.2017
ES19.07.2017
FI19.07.2017
HR19.07.2017
IT19.07.2017
LT19.07.2017
LV19.07.2017
NL19.07.2017
PL19.07.2017
RO19.07.2017
RS19.07.2017
SE19.07.2017
SI19.07.2017
SK19.07.2017
SM19.07.2017
BG19.10.2017
NO19.10.2017
GR20.10.2017
IS19.11.2017
Former [2018/24]AT19.07.2017
CZ19.07.2017
DK19.07.2017
EE19.07.2017
ES19.07.2017
FI19.07.2017
HR19.07.2017
IT19.07.2017
LT19.07.2017
LV19.07.2017
NL19.07.2017
PL19.07.2017
RO19.07.2017
RS19.07.2017
SE19.07.2017
SK19.07.2017
SM19.07.2017
BG19.10.2017
NO19.10.2017
GR20.10.2017
IS19.11.2017
Former [2018/21]AT19.07.2017
CZ19.07.2017
DK19.07.2017
ES19.07.2017
FI19.07.2017
HR19.07.2017
LT19.07.2017
LV19.07.2017
NL19.07.2017
PL19.07.2017
RS19.07.2017
SE19.07.2017
BG19.10.2017
NO19.10.2017
GR20.10.2017
IS19.11.2017
Former [2018/12]AT19.07.2017
ES19.07.2017
FI19.07.2017
HR19.07.2017
LT19.07.2017
LV19.07.2017
NL19.07.2017
PL19.07.2017
RS19.07.2017
SE19.07.2017
BG19.10.2017
NO19.10.2017
GR20.10.2017
IS19.11.2017
Former [2018/11]AT19.07.2017
ES19.07.2017
FI19.07.2017
HR19.07.2017
LT19.07.2017
NL19.07.2017
PL19.07.2017
RS19.07.2017
SE19.07.2017
BG19.10.2017
NO19.10.2017
GR20.10.2017
IS19.11.2017
Former [2018/10]AT19.07.2017
FI19.07.2017
HR19.07.2017
LT19.07.2017
NL19.07.2017
RS19.07.2017
SE19.07.2017
NO19.10.2017
Former [2018/09]FI19.07.2017
LT19.07.2017
NL19.07.2017
SE19.07.2017
NO19.10.2017
Former [2018/08]FI19.07.2017
LT19.07.2017
NL19.07.2017
NO19.10.2017
Former [2018/07]LT19.07.2017
NO19.10.2017
Documents cited:Search[A]WO03024408  (UNIV ROCHESTER [US], et al) [A] 1-5 * abstract *;
 [A]WO03037172  (GPC BIOTECH INC [US], et al) [A] 1-5 * figure 4/26; claims 3,7; sequence 248 *;
 [A]WO2004005472  (SOUTHERN RES INST [US], et al) [A] 1-5 * abstract * * page 37 *;
 [A]WO2007056188  (HARVARD COLLEGE [US], et al) [A] 1-5 * abstract * * paragraph [0072] *;
 [AD]WO2009093692  (TOAGOSEI CO LTD [JP], et al) [AD] 2,3 * abstract *;
 [A]DE102009021681  (UNIV DRESDEN TECH [DE]) [A] 1-5 * abstract *;
 [A]  - LAPPCHEN ET AL, "Probing FtsZ and Tubulin with C8-Substituted GTP Analogs Reveals Differences in Their Nucleotide Binding Sites", CHEMISTRY AND BIOLOGY, CURRENT BIOLOGY, LONDON, GB, (20080222), vol. 15, no. 2, doi:10.1016/J.CHEMBIOL.2007.12.013, ISSN 1074-5521, pages 189 - 199, XP022489110 [A] 1-5 * abstract * * page 189 - page 190, paragraph 1 *

DOI:   http://dx.doi.org/10.1016/j.chembiol.2007.12.013
 [T]  - IWAO OJIMA ET AL, "Drug discovery targeting cell division proteins, microtubules and FtsZ", BIOORGANIC & MEDICINAL CHEMISTRY, (20140901), vol. 22, no. 18, doi:10.1016/j.bmc.2014.02.036, ISSN 0968-0896, pages 5060 - 5077, XP055190224 [T] 1-5 * abstract * * page 5075 *

DOI:   http://dx.doi.org/10.1016/j.bmc.2014.02.036
International search[A]WO2009093692  (TOAGOSEI CO LTD [JP], et al);
 [A]WO2011013698  (TOAGOSEI CO LTD [JP], et al);
 [A]WO2011013699  (TOAGOSEI CO LTD [JP], et al);
 [A]  - PARADIS-BLEAU C. ET AL., "Peptide inhibitors of the essential cell division protein FtsA., Protein Engineering", DESIGN & SELECTION, (2005), vol. 18, no. 2, pages 85 - 91, XP055154920

DOI:   http://dx.doi.org/10.1093/protein/gzi008
 [A]  - PARADIS-BLEAU C. ET AL., "Identification of Pseudomonas aeruginosa FtsZ peptide inhibitors as a tool for development of novel antimicrobials.", JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, (2004), vol. 54, no. 1, pages 278 - 280, XP055154923

DOI:   http://dx.doi.org/10.1093/jac/dkh318
 [A]  - VOLLMER W. ET AL., "The prokaryotic cytoskeleton: a putative target for inhibitors and antibiotics?", APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, (2006), vol. 73, pages 37 - 47, XP019441737

DOI:   http://dx.doi.org/10.1007/s00253-006-0586-0
 [A]  - HUANG Q. ET AL., "Targeting FtsZ for anti- tuberculosis drug discovery: non-cytotoxic taxanes as novel anti-tuberculosis agents.", JOURNAL OF MEDICINAL CHEMISTRY, (2006), vol. 49, no. 2, pages 463 - 466, XP055154927

DOI:   http://dx.doi.org/10.1021/jm050920y
by applicantWO2007004869
 WO2008081812
 WO2009093692
 WO2011013698
 WO2011013699
    - PROTEIN ENGINEERING, DESIGN & SELECTION, (2005), vol. 18, no. 2, pages 85 - 91
    - JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, (2004), vol. 54, no. 1, pages 278 - 280
    - SHIMIZU ET AL., NATURE BIOTECHNOLOGY, (2001), vol. 19, pages 751 - 755
    - MADIN ET AL., PROC. NATL. ACAD. SCI. USA, (2000), vol. 97, no. 2, pages 559 - 564
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.